111 related articles for article (PubMed ID: 11830554)
1. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Angelo LS; Talpaz M; Kurzrock R
Cancer Res; 2002 Feb; 62(3):932-40. PubMed ID: 11830554
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
3. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter.
Pietrzak M; Puzianowska-Kuznicka M
Biol Chem; 2008 Apr; 389(4):383-93. PubMed ID: 18208354
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 in renal carcinoma cells is independent of pVHL.
Stickle NH; Cheng LS; Watson IR; Alon N; Malkin D; Irwin MS; Ohh M
Mutat Res; 2005 Oct; 578(1-2):23-32. PubMed ID: 15998523
[TBL] [Abstract][Full Text] [Related]
5. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
8. Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer.
Desaintes C; Hallez S; Detremmerie O; Burny A
Oncogene; 1995 Jun; 10(11):2155-61. PubMed ID: 7784059
[TBL] [Abstract][Full Text] [Related]
9. p53 transactivation through various p53-responsive elements.
Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
[TBL] [Abstract][Full Text] [Related]
10. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
[TBL] [Abstract][Full Text] [Related]
11. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.
Marreiros A; Dudgeon K; Dao V; Grimm MO; Czolij R; Crossley M; Jackson P
Oncogene; 2005 Jan; 24(4):637-49. PubMed ID: 15580298
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
[TBL] [Abstract][Full Text] [Related]
15. Ets protein Elf-1 bidirectionally suppresses transcriptional activities of the tumor suppressor Tsc2 gene and the repair-related Nth1 gene.
Honda S; Kobayashi T; Kajino K; Urakami S; Igawa M; Hino O
Mol Carcinog; 2003 Jul; 37(3):122-9. PubMed ID: 12884363
[TBL] [Abstract][Full Text] [Related]
16. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
17. [Interaction of p53 with p53 response element like binding sequence at upstream of hepatitis B virus enhancer I].
Qu JH; Zhu MH; Lin J; Ni CR; Li FM; Zhu Z; Yu GZ
Ai Zheng; 2004 May; 23(5):502-7. PubMed ID: 15142443
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion.
Lai R; el Dabbagh L; Mourad WA
Mod Pathol; 1996 Jun; 9(6):690-5. PubMed ID: 8782209
[TBL] [Abstract][Full Text] [Related]
19. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
20. Cell-type- and promoter-dependent ts phenotype of p53 Val135.
Sehgal PB; Margulies L
Oncogene; 1993 Dec; 8(12):3417-9. PubMed ID: 8247545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
